CONMED (CNMD) Competitors

$36.60 +1.11 (+3.12%)

Closing price 03:59 PM Eastern

Extended Trading

$36.60 +0.00 (+0.01%)

As of 05:32 PM Eastern

CNMD vs. MMSI, NVST, IRTC, TMDX, and LQDA

Should you buy CONMED stock or one of its competitors? MarketBeat compares CONMED with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with CONMED include Merit Medical Systems (MMSI), Envista (NVST), iRhythm Technologies (IRTC), TransMedics Group (TMDX), and Liquidia (LQDA). These companies are all part of the "medical" sector.

How does CONMED compare to Merit Medical Systems?

Merit Medical Systems (NASDAQ:MMSI) and CONMED (NYSE:CNMD) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, media sentiment, earnings, analyst recommendations and dividends.

Merit Medical Systems has a beta of 0.58, suggesting that its stock price is 42% less volatile than the broader market. Comparatively, CONMED has a beta of 0.94, suggesting that its stock price is 6% less volatile than the broader market.

In the previous week, Merit Medical Systems had 3 more articles in the media than CONMED. MarketBeat recorded 6 mentions for Merit Medical Systems and 3 mentions for CONMED. Merit Medical Systems' average media sentiment score of 1.24 beat CONMED's score of 0.00 indicating that Merit Medical Systems is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Merit Medical Systems	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CONMED	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

99.7% of Merit Medical Systems shares are held by institutional investors. 0.7% of Merit Medical Systems shares are held by company insiders. Comparatively, 0.3% of CONMED shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Merit Medical Systems presently has a consensus target price of $92.80, suggesting a potential upside of 45.82%. CONMED has a consensus target price of $43.80, suggesting a potential upside of 19.68%. Given Merit Medical Systems' stronger consensus rating and higher possible upside, analysts clearly believe Merit Medical Systems is more favorable than CONMED.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Merit Medical Systems	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
CONMED	1 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.86

Merit Medical Systems has higher revenue and earnings than CONMED. CONMED is trading at a lower price-to-earnings ratio than Merit Medical Systems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Merit Medical Systems	$1.52B	2.50	$128.49M	$2.31	27.55
CONMED	$1.37B	0.80	$47.06M	$1.77	20.68

Merit Medical Systems has a net margin of 9.03% compared to CONMED's net margin of 4.00%. CONMED's return on equity of 13.84% beat Merit Medical Systems' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Merit Medical Systems	9.03%	13.54%	7.94%
CONMED	4.00%	13.84%	6.05%

Summary

Merit Medical Systems beats CONMED on 14 of the 16 factors compared between the two stocks.

How does CONMED compare to Envista?

Envista (NYSE:NVST) and CONMED (NYSE:CNMD) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, risk, valuation, media sentiment and analyst recommendations.

Envista has a beta of 0.92, suggesting that its share price is 8% less volatile than the broader market. Comparatively, CONMED has a beta of 0.94, suggesting that its share price is 6% less volatile than the broader market.

In the previous week, Envista had 3 more articles in the media than CONMED. MarketBeat recorded 6 mentions for Envista and 3 mentions for CONMED. Envista's average media sentiment score of 0.47 beat CONMED's score of 0.00 indicating that Envista is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Envista	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CONMED	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Envista presently has a consensus price target of $28.83, suggesting a potential upside of 24.63%. CONMED has a consensus price target of $43.80, suggesting a potential upside of 19.68%. Given Envista's stronger consensus rating and higher possible upside, equities analysts clearly believe Envista is more favorable than CONMED.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Envista	0 Sell rating(s)	9 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.40
CONMED	1 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.86

CONMED has a net margin of 4.00% compared to Envista's net margin of 2.41%. CONMED's return on equity of 13.84% beat Envista's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Envista	2.41%	7.11%	3.91%
CONMED	4.00%	13.84%	6.05%

CONMED has lower revenue, but higher earnings than Envista. CONMED is trading at a lower price-to-earnings ratio than Envista, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Envista	$2.72B	1.38	$47M	$0.41	56.43
CONMED	$1.37B	0.80	$47.06M	$1.77	20.68

Summary

Envista beats CONMED on 8 of the 14 factors compared between the two stocks.

How does CONMED compare to iRhythm Technologies?

iRhythm Technologies (NASDAQ:IRTC) and CONMED (NYSE:CNMD) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, valuation, institutional ownership, analyst recommendations, earnings and risk.

CONMED has higher revenue and earnings than iRhythm Technologies. iRhythm Technologies is trading at a lower price-to-earnings ratio than CONMED, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iRhythm Technologies	$747.14M	4.88	-$44.55M	-$0.86	N/A
CONMED	$1.37B	0.80	$47.06M	$1.77	20.68

CONMED has a net margin of 4.00% compared to iRhythm Technologies' net margin of -3.53%. CONMED's return on equity of 13.84% beat iRhythm Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iRhythm Technologies	-3.53%	-10.26%	-1.39%
CONMED	4.00%	13.84%	6.05%

iRhythm Technologies has a beta of 1.33, indicating that its stock price is 33% more volatile than the broader market. Comparatively, CONMED has a beta of 0.94, indicating that its stock price is 6% less volatile than the broader market.

iRhythm Technologies currently has a consensus price target of $191.85, indicating a potential upside of 72.93%. CONMED has a consensus price target of $43.80, indicating a potential upside of 19.68%. Given iRhythm Technologies' stronger consensus rating and higher possible upside, equities analysts clearly believe iRhythm Technologies is more favorable than CONMED.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iRhythm Technologies	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.93
CONMED	1 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.86

In the previous week, iRhythm Technologies had 6 more articles in the media than CONMED. MarketBeat recorded 9 mentions for iRhythm Technologies and 3 mentions for CONMED. iRhythm Technologies' average media sentiment score of 1.34 beat CONMED's score of 0.00 indicating that iRhythm Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
iRhythm Technologies	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
CONMED	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

iRhythm Technologies beats CONMED on 8 of the 15 factors compared between the two stocks.

How does CONMED compare to TransMedics Group?

CONMED (NYSE:CNMD) and TransMedics Group (NASDAQ:TMDX) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, profitability, institutional ownership, risk, dividends and earnings.

In the previous week, CONMED and CONMED both had 3 articles in the media. TransMedics Group's average media sentiment score of 0.39 beat CONMED's score of 0.00 indicating that TransMedics Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CONMED	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
TransMedics Group	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

CONMED currently has a consensus target price of $43.80, suggesting a potential upside of 19.68%. TransMedics Group has a consensus target price of $135.00, suggesting a potential upside of 97.54%. Given TransMedics Group's stronger consensus rating and higher probable upside, analysts clearly believe TransMedics Group is more favorable than CONMED.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CONMED	1 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.86
TransMedics Group	0 Sell rating(s)	6 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50

TransMedics Group has a net margin of 27.04% compared to CONMED's net margin of 4.00%. TransMedics Group's return on equity of 22.38% beat CONMED's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CONMED	4.00%	13.84%	6.05%
TransMedics Group	27.04%	22.38%	8.46%

CONMED has a beta of 0.94, indicating that its stock price is 6% less volatile than the broader market. Comparatively, TransMedics Group has a beta of 2.07, indicating that its stock price is 107% more volatile than the broader market.

TransMedics Group has lower revenue, but higher earnings than CONMED. TransMedics Group is trading at a lower price-to-earnings ratio than CONMED, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CONMED	$1.37B	0.80	$47.06M	$1.77	20.68
TransMedics Group	$605.49M	3.90	$190.29M	$4.40	15.53

99.7% of TransMedics Group shares are owned by institutional investors. 0.3% of CONMED shares are owned by company insiders. Comparatively, 6.9% of TransMedics Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

TransMedics Group beats CONMED on 13 of the 15 factors compared between the two stocks.

How does CONMED compare to Liquidia?

CONMED (NYSE:CNMD) and Liquidia (NASDAQ:LQDA) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends, media sentiment and earnings.

In the previous week, Liquidia had 40 more articles in the media than CONMED. MarketBeat recorded 43 mentions for Liquidia and 3 mentions for CONMED. Liquidia's average media sentiment score of 0.63 beat CONMED's score of 0.00 indicating that Liquidia is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CONMED	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Liquidia	15 Very Positive mention(s)	7 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

64.5% of Liquidia shares are owned by institutional investors. 0.3% of CONMED shares are owned by insiders. Comparatively, 25.6% of Liquidia shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Liquidia has a net margin of 7.74% compared to CONMED's net margin of 4.00%. Liquidia's return on equity of 46.82% beat CONMED's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CONMED	4.00%	13.84%	6.05%
Liquidia	7.74%	46.82%	7.06%

CONMED has a beta of 0.94, suggesting that its stock price is 6% less volatile than the broader market. Comparatively, Liquidia has a beta of 0.41, suggesting that its stock price is 59% less volatile than the broader market.

CONMED presently has a consensus price target of $43.80, suggesting a potential upside of 19.68%. Liquidia has a consensus price target of $49.33, suggesting a potential downside of 13.40%. Given CONMED's higher probable upside, analysts plainly believe CONMED is more favorable than Liquidia.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CONMED	1 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.86
Liquidia	2 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	2.92

CONMED has higher revenue and earnings than Liquidia. CONMED is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CONMED	$1.37B	0.80	$47.06M	$1.77	20.68
Liquidia	$158.32M	32.00	-$68.92M	$0.14	406.93

Summary

Liquidia beats CONMED on 12 of the 17 factors compared between the two stocks.

Get CONMED News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CNMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CNMD vs. The Competition

Export

Metric	CONMED	MED/DENTAL Industry	Medical Sector	NYSE Exchange
Market Cap	$1.07B	$14.98B	$6.25B	$22.75B
Dividend Yield	N/A	2.15%	2.80%	4.13%
P/E Ratio	20.68	15.81	20.86	29.86
Price / Sales	0.80	2.20	549.88	24.05
Price / Cash	4.93	12.77	27.48	18.80
Price / Book	1.10	3.06	9.67	4.59
Net Income	$47.06M	$534.24M	$3.56B	$1.07B
7 Day Performance	3.72%	5.66%	-1.91%	-1.35%
1 Month Performance	-6.42%	-0.41%	-2.65%	-1.29%
1 Year Performance	-39.23%	-6.94%	31.17%	21.88%

CONMED Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CNMD CONMED	2.363 of 5 stars	$36.60 +3.1%	$43.80 +19.7%	-41.2%	$1.07B	$1.37B	20.68	3,900	Analyst Forecast
MMSI Merit Medical Systems	4.1445 of 5 stars	$62.01 flat	$92.80 +49.7%	-37.9%	$3.70B	$1.54B	26.84	7,500	Positive News High Trading Volume
NVST Envista	3.6896 of 5 stars	$25.82 -2.0%	$28.25 +9.4%	+27.4%	$4.29B	$2.72B	92.20	12,000
IRTC iRhythm Technologies	4.5815 of 5 stars	$119.18 -1.3%	$193.38 +62.3%	-19.1%	$3.92B	$787.85M	N/A	2,400	Positive News Analyst Forecast
TMDX TransMedics Group	4.0171 of 5 stars	$97.08 -2.9%	$152.33 +56.9%	-48.0%	$3.45B	$605.49M	19.81	210

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:CNMD) was last updated on 5/18/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CONMED (CNMD) Competitors

CNMD vs. MMSI, NVST, IRTC, TMDX, and LQDA

How does CONMED compare to Merit Medical Systems?

Summary

How does CONMED compare to Envista?

Summary

How does CONMED compare to iRhythm Technologies?

Summary

How does CONMED compare to TransMedics Group?

Summary

How does CONMED compare to Liquidia?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNMD vs. The Competition

CONMED Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CONMED (CNMD) Competitors

CNMD vs. MMSI, NVST, IRTC, TMDX, and LQDA

How does CONMED compare to Merit Medical Systems?

Which has more risk and volatility, MMSI or CNMD?

Does the media refer more to MMSI or CNMD?

Do institutionals and insiders have more ownership in MMSI or CNMD?

Do analysts rate MMSI or CNMD?

Which has better valuation and earnings, MMSI or CNMD?

Is MMSI or CNMD more profitable?

Summary

How does CONMED compare to Envista?

Which has more risk and volatility, NVST or CNMD?

Does the media refer more to NVST or CNMD?

Do analysts prefer NVST or CNMD?

Is NVST or CNMD more profitable?

Which has stronger earnings & valuation, NVST or CNMD?

Summary

How does CONMED compare to iRhythm Technologies?

Which has better earnings & valuation, IRTC or CNMD?

Is IRTC or CNMD more profitable?

Which has more risk & volatility, IRTC or CNMD?

Do analysts prefer IRTC or CNMD?

Does the media refer more to IRTC or CNMD?

Summary

How does CONMED compare to TransMedics Group?

Does the media prefer CNMD or TMDX?

Do analysts prefer CNMD or TMDX?

Is CNMD or TMDX more profitable?

Which has more risk and volatility, CNMD or TMDX?

Which has stronger earnings and valuation, CNMD or TMDX?

Do insiders and institutionals hold more shares of CNMD or TMDX?

Summary

How does CONMED compare to Liquidia?

Does the media prefer CNMD or LQDA?

Do institutionals & insiders hold more shares of CNMD or LQDA?

Is CNMD or LQDA more profitable?

Which has more volatility and risk, CNMD or LQDA?

Do analysts prefer CNMD or LQDA?

Which has better valuation and earnings, CNMD or LQDA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNMD vs. The Competition

CONMED Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools